2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer

被引：7
作者：
So, Alan, I [1 ]
Chi, Kim [2 ]
Danielson, Brita [3 ]
Fleshner, Neil E. [4 ]
Kinnaird, Adam [5 ]
Kapoor, Anil [6 ]
Niazi, Tamim [7 ]
Pouliot, Frederic [8 ]
Rendon, Ricardo A. [9 ]
Shayegan, Bobby [6 ]
Sridhar, Srikala S. [10 ]
Vigneault, Eric [11 ]
Saad, Fred [12 ]
机构：
[1] Univ British Columbia, Dept Urol Sci, Vancouver, BC, Canada
[2] BC Canc, Vancouver, BC, Canada
[3] Univ Alberta, Dept Oncol, Div Radiat Oncol, Edmonton, AB, Canada
[4] Univ Toronto, Dept Surg, Div Urol, Toronto, ON, Canada
[5] Univ Alberta, Dept Surg, Div Urol, Edmonton, AB, Canada
[6] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON, Canada
[7] McGill Univ, Dept Oncol, Div Radiat Oncol, Montreal, PQ, Canada
[8] Univ Laval, Dept Surg, Div Urol, Quebec City, PQ, Canada
[9] Dalhousie Univ, Dept Urol, Halifax, NS, Canada
[10] Univ Toronto, Princess Margaret Canc Ctr, Div Med Oncol, Toronto, ON, Canada
[11] Univ Laval, CHUQ, Dept Radiat Oncol, Quebec City, PQ, Canada
[12] Univ Montreal, Dept Surg, Div Urol, Montreal, PQ, Canada
来源：
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL | 2022年 / 16卷 / 12期
关键词：
ANDROGEN-DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; INCREASED SURVIVAL; ZOLEDRONIC ACID; PLUS PREDNISONE; BONE LOSS; MEN; ENZALUTAMIDE; DOCETAXEL; ABIRATERONE;
D O I：
10.5489/cuaj.8148
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E581 / E589
页数：9
相关论文
共 47 条
  • [31] Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
    James, N. D.
    de Bono, J. S.
    Spears, M. R.
    Clarke, N. W.
    Mason, M. D.
    Dearnaley, D. P.
    Ritchie, A. W. S.
    Amos, C. L.
    Gilson, C.
    Jones, R. J.
    Matheson, D.
    Miliman, R.
    Attard, G.
    Chowdhury, S.
    Cross, W. R.
    Gillessen, S.
    Parker, C. C.
    Russell, J. M.
    Berthold, D. R.
    Brawley, C.
    Adab, F.
    Aung, S.
    Birtle, A. J.
    Bowen, J.
    Brock, S.
    Chakraborti, P.
    Ferguson, C.
    Gale, J.
    Gray, E.
    Hingorani, M.
    Hoskin, P. J.
    Lester, J. F.
    Malik, Z. I.
    McKinna, F.
    McPhail, N.
    Money-Kyrle, J.
    O'Sullivan, J.
    Parikh, O.
    Protheroe, A.
    Robinson, A.
    Srihari, N. N.
    Thomas, C.
    Wagstaff, J.
    Wylie, J.
    Zarkar, A.
    Parmar, M. K. B.
    Sydes, M. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) : 338 - 351
  • [32] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
    James, Nicholas D.
    Sydes, Matthew R.
    Clarke, Noel W.
    Mason, Malcolm D.
    Dearnaley, David P.
    Spears, Melissa R.
    Ritchie, Alastair W. S.
    Parker, Christopher C.
    Russell, J. Martin
    Attard, Gerhardt
    de Bono, Johann
    Cross, William
    Jones, Rob J.
    Thalmann, George
    Amos, Claire
    Matheson, David
    Millman, Robin
    Alzouebi, Mymoona
    Beesley, Sharon
    Birtle, Alison J.
    Brock, Susannah
    Cathomas, Richard
    Chakraborti, Prabir
    Chowdhury, Simon
    Cook, Audrey
    Elliott, Tony
    Gale, Joanna
    Gibbs, Stephanie
    Graham, John D.
    Hetherington, John
    Hughes, Robert
    Laing, Robert
    McKinna, Fiona
    McLaren, Duncan B.
    O'Sullivan, Joe M.
    Parikh, Omi
    Peedell, Clive
    Protheroe, Andrew
    Robinson, Angus J.
    Srihari, Narayanan
    Srinivasan, Rajaguru
    Staffurth, John
    Sundar, Santhanam
    Tolan, Shaun
    Tsang, David
    Wagstaff, John
    Parmar, Mahesh K. B.
    [J]. LANCET, 2016, 387 (10024) : 1163 - 1177
  • [33] Treatment of Primary in Metastatic Prostate Cancer What Is the Standard of Care?
    Joseph, Nuradh
    Anjanappa, Milan
    Choudhury, Ananya
    [J]. CANCER JOURNAL, 2020, 26 (01) : 83 - 86
  • [34] Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review
    Kunath, F.
    Goebell, P. J.
    Wullich, B.
    Sikic, D.
    Kahlmeyer, A.
    [J]. WORLD JOURNAL OF UROLOGY, 2020, 38 (03) : 601 - 611
  • [35] Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
    Kyriakopoulos, Christos E.
    Chen, Yu-Hui
    Carducci, Michael A.
    Liu, Glenn
    Jarrard, David F.
    Hahn, Noah M.
    Shevrin, Daniel H.
    Dreicer, Robert
    Hussain, Maha
    Eisenberger, Mario
    Kohli, Manish
    Plimack, Elizabeth R.
    Vogelzang, Nicholas J.
    Picus, Joel
    Cooney, Matthew M.
    Garcia, Jorge A.
    DiPaola, Robert S.
    Sweeney, Christopher J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (11) : 1080 - +
  • [36] De novo metastatic castration sensitive prostate cancer: State of art and future perspectives
    Mosillo, Claudia
    Iacovelli, Roberto
    Ciccarese, Chiara
    Fantinel, Emanuela
    Bimbatti, Davide
    Brunelli, Matteo
    Bisogno, Iolanda
    Kinspergher, Stefania
    Buttigliero, Consuelo
    Tucci, Marcello
    Caffo, Orazio
    Tortora, Giampaolo
    [J]. CANCER TREATMENT REVIEWS, 2018, 70 : 67 - 74
  • [37] Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials
    Niraula, Saroj
    Le, Lisa W.
    Tannock, Ian F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 2029 - U342
  • [38] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
    Parker, Christopher C.
    James, Nicholas D.
    Brawley, Christopher D.
    Clarke, Noel W.
    Hoyle, Alex P.
    Ali, Adnan
    Ritchie, Alastair W. S.
    Attard, Gerhardt
    Chowdhury, Simon
    Cross, William
    Dearnaley, David P.
    Gillessen, Silke
    Gilson, Clare
    Jones, Robert J.
    Langley, Ruth E.
    Malik, Zafar I.
    Mason, Malcolm D.
    Matheson, David
    Millman, Robin
    Russell, J. Martin
    Thalmann, George N.
    Amos, Claire L.
    Alonzi, Roberto
    Bahl, Amit
    Birtle, Alison
    Din, Omar
    Douis, Hassan
    Eswar, Chinnamani
    Gale, Joanna
    Gannon, Melissa R.
    Jonnada, Sai
    Khaksar, Sara
    Lester, Jason F.
    O'Sullivan, Joe M.
    Parikh, Omi A.
    Pedley, Ian D.
    Pudney, Delia M.
    Sheehan, Denise J.
    Srihari, Narayanan Nair
    Tran, Anna T. H.
    Parmar, Mahesh K. B.
    Sydes, Matthew R.
    [J]. LANCET, 2018, 392 (10162) : 2353 - 2366
  • [39] Rexer H, 2015, UROLOGE, V54, P1613, DOI 10.1007/s00120-015-4020-z
  • [40] Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    Ryan, Charles J.
    Smith, Matthew R.
    Fizazi, Karim
    Saad, Fred
    Mulders, Peter F. A.
    Sternberg, Cora N.
    Miller, Kurt
    Logothetis, Christopher J.
    Shore, Neal D.
    Small, Eric J.
    Carles, Joan
    Flaig, Thomas W.
    Taplin, Mary-Ellen
    Higano, Celestia S.
    de Souza, Paul
    de Bono, Johann S. s
    Griffin, Thomas W.
    De Porre, Peter
    Yu, Margaret K.
    Park, Youn C.
    Li, Jinhui
    Kheoh, Thian
    Naini, Vahid
    Molina, Arturo
    Rathkopf, Dana E.
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 152 - 160
12345